Cell and gene therapies share fundamental objectives with conventional biologics. Their common challenges offer a natural starting point to solving downstream bottlenecks.
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
- The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs
- Single-Use Standards Are Maturing, But The Process Remains King
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Fast And Accurate Detection Of Alzheimer's Disease Targets
In this study, the detection of three Alzheimer’s disease targets are highlighted: Human BDNF (Brain-derived neurotrophic factor), Tau, and TREM2 (Triggering receptor expressed on myeloid cells 2).
-
Analysis Of DNA Integrity And Stability Using Digital PCR
Digital PCR offers precise, inhibitor-resistant DNA quantification and genome integrity assessment. Discover how this method enhances accuracy and reproducibility, especially in AAV analysis, using multiplexed targets and Poisson-based calculations.
-
Intuitive Bioprocess Scale-Up From Bench Scale To Pilot Scale
This study explores scaling a high-demand fed-batch process from bench to pilot scale, highlighting control parameter differences at 50L and 500L while maintaining consistent growth and product titers.
-
Characterization Of The Colon Intestine-Chip
Learn about the development and characterization of Organ-Chips and what makes them the most comprehensive model of the colonic epithelial-endothelial interface that is commercially available.
-
Anaerobic Cultivation Processes Of Probiotic Bacteria
Cultivate oxygen-sensitive probiotics with precision using real-time monitoring, microfluidic feeding, and pH control for reproducible growth and optimized microbiome and fermentation research.
-
Handle Single-Use Technology Biopharma Waste: Data Sharing, Collaboration
Learn more about data sharing and collaboration to enable a better environmental impact of single-use technologies (SUTs) and quantifying the single-use plastic waste generated when manufacturing mAbs.
-
Performance Of HEKima™ Adherent HEK Cell Medium
Explore the performance of a serum-free medium designed for HEK-293 cells, comparing its efficacy to traditional media for protein expression and cell proliferation.
-
Triple-Negative Breast Cancer: Global Clinical Trial Landscape
With over 1,500 TNBC-focused clinical trials since 2019, research efforts into Triple-negative breast cancer (TNBC) treatments are accelerating despite challenges such as drug resistance.
-
hiPSC Aggregate Expansion In Stirred-Tank Bioreactors
Learn about a bioreactor-based Human Induced Pluripotent Stem Cell (hiPSC) expansion workflow with the potential to improve cell therapy applications.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
NEWSLETTER ARCHIVE
- 02.06.26 -- New Podcast Episodes: Putting Pressure On CDMOs, BoB@JPM, Building Safer CRISPR Medicines For CVD
- 02.06.26 -- Sales & Operations Planning For Small Teams: Aligning Clinical Supply
- 02.05.26 -- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- 02.04.26 -- Balancing The Elements: Strategies For Resilient Clinical Research
- 02.04.26 -- In Vivo's Biggest Threat — Comparison To Old Models
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections